2.A case of neoadjuvant chemotherapy with taxol / carboplatin in advanced epithelial ovarian cancer.
Korean Journal of Obstetrics and Gynecology 2000;43(10):1874-1878
No abstract available.
Carboplatin*
;
Drug Therapy*
;
Ovarian Neoplasms*
;
Paclitaxel*
3.Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature.
Seiji MABUCHI ; Kenichirou MORISHIGE ; Takayuki ENOMOTO ; Tadashi KIMURA
Journal of Gynecologic Oncology 2010;21(2):93-96
OBJECTIVE: The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an initial treatment in patients with the International Federation of Gynecology and Obstetrics (FIGO) stage IVb cervical cancer. METHODS: We retrospectively reviewed seven patients with stage IVb cervical cancer who have been primarily treated with TC. The activity and the toxicity were evaluated. Response rate was the main endpoint. RESULTS: Overall, the treatment of TC was well tolerated. The overall response rate was 71.4% (2 complete response, 3 partial response). Although grade 3-4 hematologic toxicities were observed in 3 out of 7 patients (42.8%), no patients experienced grade 3-4 non-hematologic toxicities. When we combined our present results with the previous reports, the overall response rate of TC is 63.6%. CONCLUSION: TC is active and well tolerated in patients FIGO stage IVb cervical cancer. This combination may be considered as an initial treatment regimen in this patient population.
Carboplatin
;
Gynecology
;
Humans
;
Obstetrics
;
Paclitaxel
;
Retrospective Studies
;
Uterine Cervical Neoplasms
4.A Case of Primary Peritoneal Serous Papillary Carcinoma.
So Hee CHEON ; Yun Jung LEE ; Soo Young HUR ; In KWEON ; Sa Jin KIM ; Eun Jung KIM ; Jeana KIM ; Sung Eun NAMKOONG ; Jong Sup PARK
Korean Journal of Obstetrics and Gynecology 2004;47(7):1427-1432
Primary peritoneal serous papillary carcinoma (PPSPC) is a rare tumor that originates from a single or multicentric foci of peritoneum. Histologically the disease resembles primary serous papillary carcinoma of the ovary, but either involves the ovarian surface microscopically only or spares the ovaries entirely. Currently PPSPC is evaluated, staged and treated in the same way as epithelial ovarian cancer. We experienced one case of primary peritoneal serous papillary carcinoma which achieved a complete remission with carboplatin and paclitaxel, and report this with brief review of the literatures.
Carboplatin
;
Carcinoma, Papillary*
;
Female
;
Ovarian Neoplasms
;
Ovary
;
Paclitaxel
;
Peritoneum
5.Therapy-Related Myelodysplastic Syndromes in an Ovarian Carcinoma Patient Following Treatment with Paclitaxel- and Carboplatin-Based Regimens
Masahiro MURAKAMI ; Hiroshi IKAWA
Journal of the Japanese Association of Rural Medicine 2008;57(6):873-877
Progress in chemotherapeutic strategy has significantly decreased side effects of the drugs used and greatly added to survival rates for ovarian cancer. On the other hand, the occurrence of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been reported after long-term chemotherapy. We encountered a case of therapy-related MDS that developed as a consequence of chemotherapy. A 59-year-old woman (gravida 2, para 2) stage IIIc ovarian cancer received three courses of paclitaxel and carboplatin therapy (TC) prior to primary surgery, and 16 courses of weekly TC as adjuvant chemotherapy. She exhibited pacritaxel-associated hypersensitivity reactions in the last course, so that chemotherapy was discontinued. Following three mouths of remission, a sudden rise in her tumor markers and an increase in the size of her pelvic lymphonode were discovered on PET-CT. She recieved multiple courses of chemotherary of docetaxel/carboplatin, weekly docetaxel, docetaxel/briplatin and Gemcitabin/Irinotecan between four months. In 30 months after diagnosis, complete blood count showed hemoglobin 7.7 g/dl; white cell count 4,310/μl; and platelet 7.9×104/μl. A bone marrow examination revealed MDS. She then decided against further chemotherapy, opting instead for palliative care. Fortunately, up to the present, she has not developed AML.
Therapeutic procedure
;
Chemotherapy-Oncologic Procedure
;
Carboplatin
;
Ovarian Cancer
;
L
6.Determination of carboplatin dose by area under the curve in combination chemotherapy for senile non-small cell lung cancer.
Tiejun, YIN ; Qingqing, LIU ; Changyao, HU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2007;27(6):710-2
To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg.Ml(-1).min(-1) in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (III/IV) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBP, Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg.mL(-1).min(-1) of area under the concentration-time curve (AUC). Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg.mL(-1).min(-1) by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg.mL(-1).min(-1) by AUC may be too high for Chinese senile patients with non-small cell lung cancer.
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Area Under Curve
;
Carboplatin/*administration & dosage
;
Carboplatin/adverse effects
;
Carcinoma, Non-Small-Cell Lung/*drug therapy
;
Lung Neoplasms/*drug therapy
7.The Effect of Levofloxacin on the Survival of Ovarian Cancer Cells with or Without Carboplatin Under Hypoxic Condition.
Sung Yun HONG ; Ju Hyun PARK ; Eun Jin KIM ; Jong Won LEE ; Suk Bong KOH ; Tee Sung LEE
Korean Journal of Obstetrics and Gynecology 2003;46(8):1517-1524
In solid tumor, there is a hypoxic region where oxygen supply is insufficient. In this study, we found that one of the quinolone antibiotics, levofloxacin, made a human ovarian cancer cells, SK-OV-3, resistant to hypoxia, even in the presence of a platinum-based anti-cancer therapeutic, carboplatin; when the cells (2 X 10(5) cells/12 well multi culture dish) were grown in no glucose medium (0 g/l) under hypoxia (1% O2), all the cells became dead after 24 hours of culture in the absence of levofloxacin and carboplatin, whereas the cells still survived, at least, until 36 hours of culture in the presence of levofloxacin (10-100 microgram/ml) alone or in combination with carboplatin. The results might have some implications in treating solid tumor; if cancer patients should be treated for infection with antibiotics, quinolone antibiotics can aggravate tumor by making cancer cells more resistant to hypoxia. This is also true even when a patient is treated with carboplatin. Therefore, the results strongly suggest that we should be careful in choosing antibiotics when they are used for cancer patients. In this regard, our work could be a new guideline in choosing antibiotics when antibiotics are applied for treating cancer patients.
Anoxia
;
Anti-Bacterial Agents
;
Carboplatin*
;
Cell Survival
;
Glucose
;
Humans
;
Levofloxacin*
;
Ovarian Neoplasms*
;
Oxygen
8.Docetaxel and Carboplatin Combination Chemotherapy against Persistent or Recurrent Ovarian Cancer as 2nd or more line Chemotherapy.
Young Hwan KIM ; Hong Cheun SHIN ; Sun Nie AHN ; Chun June LEE ; Won Gyu KIM
Korean Journal of Obstetrics and Gynecology 2004;47(11):2123-2130
OBJECTIVE: We evaluated the effects and toxicities of docetaxel-carboplatin combination chemotherapy against recurrent or persistent ovarian cancer who were previously heavily treated with one or more lines of chemotherapy. METHODS: Sixteen patients with a recurrent or persistent ovarian cancer, previously received first or more line chemotherapy, had been treated with docetaxel-carboplatin combination chemotherapy at Kosin Medical Center from December 2001 to May 2003. The docetaxel-carboplatin combination chemotherapy consists of docetaxel 75 mg/m2 and carboplatin 450 mg/m2 given i.v. every 3-4 weeks. The response of patients was evaluated with the tumor marker (serum CA-125) and imaging studies (ultrasonogram, CT, MRI). The toxicities were defined according to the WHO toxicity criteria. RESULTS: The overall response rate was 50% (8/16). Eight patients were evaluable for response by WHO criteria. The response rate by WHO criteria was 37.5% (3/8). In detail, complete response was 12.5%, partial response was 25%, stable disease was 37.5% and progressive disease was 25%. The serologic CA-125 response rate was 50% (8/16), in detail serologic partial response was 50%, and serologic stable disease was 31% and serologic progressive disease was 19%. The median response duration was 10 months (3 to 17 months), the median time to response was 1 month (1/2 to 2 months) and the median time to re-progression was 5 months (3 to 7 months). The most common toxicity was gastrointestinal toxicity and the bone marrow suppression was proved as a most serious side effect. CONCLUSION: The docetaxel-carboplatin chemotherapy as a 2nd or more lines regimen against heavily pre-treated recurrent or persistent ovarian cancer is considerable but was associated significant gastrointestinal and bone marrow side effects. Routine premedication is recommended.
Bone Marrow
;
Carboplatin*
;
Drug Therapy*
;
Drug Therapy, Combination*
;
Humans
;
Ovarian Neoplasms*
;
Premedication
9.Salvage therapy with Taxol in Patients with Ovarian carcinoma after Failure of Platinum-Based Chemotherapy.
Yong Beom KIM ; Dae Yeon KIM ; Sang Young RYU ; Jae Weon KIM ; Noh Hyun PARK ; Yong Sang SONG ; Soon Beom KANG ; Hyo Pyo LEE
Korean Journal of Gynecologic Oncology and Colposcopy 1997;8(2):168-174
BACKGROUND & AIMS: Management of ovarian carcinoma presents most commonly by surgery and subsequent platinum-based chemotherapy, but most patients will have either residual or recurrent disease. Taxol, a new antimicrotubule agent, has been indicated as a salvage measure after failure of first-line or subsequent chemotherapy. The purpose of this study is to investigate the efficacy and toxicity of Taxol used as a salvage therapy. MATERIALS & METHODS: Between January 1994 and Jun 1996, 19 patients aged 38-64 years(median 52) with ovarian carcinoma were given Taxol-containing regimen. Taxol was administered at a dose of 135mg/m2 intravenously with cisplatin or carboplatin every 3 weeks. The patients who treated with Taxol only were received 175mg/m2 intravenously with same interval. The median treatment cycle was 6.6 cycles(range, 3 to 15 cycles). Patient's response were evaluated with tumor marker(CA-125) and CT or MRI before and after chemotherapy. Responses and toxicities were defined according to the Gynecologic Oncology Group criteria. (continue)
Carboplatin
;
Cisplatin
;
Drug Therapy*
;
Humans
;
Magnetic Resonance Imaging
;
Ovarian Neoplasms
;
Paclitaxel*
;
Salvage Therapy*
10.A case of successful salvage chemotherapy of recurrent ovarian sertoli-leydig cell tumor.
Soyi LIM ; Na Rae KIM ; Kwang Beom LEE
Obstetrics & Gynecology Science 2013;56(3):198-200
Sertoli-Leydig tumors tend to relapse early and due to their rarity, limited data are available regarding a role of chemotherapy in the management of Sertoli-Leydig cell tumors. We present a case of recurrent ovarian Sertoli-Leydig cell tumor whose salvage treatment was successful with paclitaxel and carboplatin chemotherapy.
Carboplatin
;
Female
;
Ovary
;
Paclitaxel
;
Recurrence
;
Salvage Therapy
;
Sertoli-Leydig Cell Tumor